- Home
- FLYE vs LYRA Comparison
FLYE vs LYRA Comparison
Compare FLYE & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- LYRA
- Stock Information
- Founded
- FLYE 2018
- LYRA 2005
- Country
- FLYE United States
- LYRA United States
- Employees
- FLYE N/A
- LYRA N/A
- Industry
- FLYE Aerospace
- LYRA Medical/Dental Instruments
- Sector
- FLYE Industrials
- LYRA Health Care
- Exchange
- FLYE Nasdaq
- LYRA Nasdaq
- Market Cap
- FLYE 8.5M
- LYRA 7.6M
- IPO Year
- FLYE 2024
- LYRA 2020
- Fundamental
- Price
- FLYE $4.06
- LYRA $3.05
- Analyst Decision
- FLYE
- LYRA Hold
- Analyst Count
- FLYE 0
- LYRA 1
- Target Price
- FLYE N/A
- LYRA $16.00
- AVG Volume (30 Days)
- FLYE 55.2K
- LYRA 33.6K
- Earning Date
- FLYE 11-19-2025
- LYRA 11-12-2025
- Dividend Yield
- FLYE N/A
- LYRA N/A
- EPS Growth
- FLYE N/A
- LYRA N/A
- EPS
- FLYE N/A
- LYRA N/A
- Revenue
- FLYE $22,881,935.00
- LYRA $600,000.00
- Revenue This Year
- FLYE N/A
- LYRA N/A
- Revenue Next Year
- FLYE N/A
- LYRA $106.28
- P/E Ratio
- FLYE N/A
- LYRA N/A
- Revenue Growth
- FLYE N/A
- LYRA N/A
- 52 Week Low
- FLYE $3.83
- LYRA $3.03
- 52 Week High
- FLYE $166.00
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- FLYE 56.83
- LYRA 17.20
- Support Level
- FLYE $5.37
- LYRA $5.40
- Resistance Level
- FLYE $4.21
- LYRA $3.99
- Average True Range (ATR)
- FLYE 0.34
- LYRA 0.34
- MACD
- FLYE -0.20
- LYRA -0.07
- Stochastic Oscillator
- FLYE 10.09
- LYRA 0.00
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.